Multiple sclerosis, immunomodulation, and immunizations
Balancing the benefits
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published January 30, 2015.
Article Versions
- Previous version (January 30, 2015 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Myla D. Goldman, MD, MSc and
- Robert T. Naismith, MD
- Myla D. Goldman, MD, MSc and
Novartis Pharmeceuticals Biogen, IDEC.
NONE
NONE
10/2012 - present: Associate editor, Therapeutic Advances in Neurological Disorders 6/2008 ? 3/2012 Member, Editorial Board, International Journal of MS Care
NONE
NONE
NONE
Concert Pharmaceuticals Questcor
NONE
Acroda Therapeutics: Travel and Lodging Reimbursement
NONE
Institutional Contracts *Biogen, Idec *Novartis Pharm.
Title: K-23 Career Development Award: Validation of a Motor Fatigue measure in Multiple Sclerosis Agency: NINDS Period: Jan 2010 - Dec 2015 Role: Principal Investigator Title: Personalized Signal Processing for Early Diagnosis of Mobility Impairment Agency: National Science Foundation Period: 2012-2015 Role: Advisor
NONE
ziMS Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Robert T. Naismith, MD
1) Acorda Therapeutics
NONE
1) Acorda Therapeutics, speaker honoraria and travel (commercial) 2) Bayer Healthcare, speaker honoraria and travel (commercial) 3) Biogen IDEC, speaker honoraria and travel (commercial) 4) Genzyme Corporation, speaker honoraria and travel (commercial) 5) National MS Society, speaker honoraria and travel (not- for profit) 6) Consortium MS Centers, speaker honoraria and travel (not-for-profit) 7) EMD Serono, consulting honoraria and travel (commercial) 8) Questcor Therapeutics, consulting honoraria and travel (commercial) 9) Genentech, consulting honoraria (commercial) 10) Novartis, consulting honoraria and travel (commercial)
Journal Watch 2010-present, Associate Editor
NONE
NONE
NONE
NONE
1) Acorda Therapeutics (commercial) 2) Bayer Healthcare (commercial) 3) Biogen Idec (commercial) 4) Genzyme Corporation (commercial)
NONE
NONE
Acorda Therapeutics - Washington University site PI for national Fampridine SR clinical trial, 2004-2010. Dalfampridine for vision after optic neuritis in MS, 2011- present.
NONE
NONE
National MS Society
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (M.D.G.), University of Virginia, Charlottesville; and the Department of Neurology (R.T.N.), Washington University, St. Louis, MO.
- Correspondence to Dr. Goldman: mdg3n{at}virginia.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.